Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002 Dec;130(3):363-9.
doi: 10.1046/j.1365-2249.2002.02016.x.

Discovery of immunopotentiatory drugs: current and future strategies

J Rhodes  1
Affiliations
Review

Discovery of immunopotentiatory drugs: current and future strategies

J Rhodes. Clin Exp Immunol. 2002 Dec.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Human toll-like receptors 1–9, expressed on dendritic cells and other APC, mediate the detection of pathogen associated molecular patterns and the up-regulation of costimulatory molecules and cytokines in response to these pathogen-associated signals. The low-molecular-weight immunopotentiatory drugs imiquimod and resiquimod signal via TLR-7 (while resiquimod can also signal via human, but not murine, TLR-8 at higher drug concentrations).
Fig. 2
Fig. 2
Activated neutrophils, which mediate the acute phase of innate immune responses, use the myeloperoxidase, hydrogen peroxide, chloride pathway to convert l-tyrosine to p-hydroxyphenylacetaldehyde which partitions to plasma membranes to forms Schiff bases with ɛ-amino groups. In separate studies the latter process has been shown to costimulate T-cells and amplify Th1 responses in the same way as the immunopotentiatory drug tucaresol.
See this image and copyright information in PMC

References

    1. Masihi KN. Immunomodulatory agents for the prophylaxis and therapy of infections. Int J Antimicrob Agents. 2000;14:181–91. - PubMed
    1. Sykes RB. Rock Carling Fellowhip of the Nuffield Trust. London: The Stationary Office; 2000. New medicines, the practice of medicine and public policy.
    1. Buckley RH. Primary Immunodeficiency Diseases. In: Paul W, editor. Fundamental Immunology. 4. New York: Lippincot-Raven; 1999. pp. 1427–53.
    1. Miller RL, Gerster JF, Owens ML, Slade HB, Tomami MA. Imiquimod applied topically. a novel class of immune response modifier and new class of drug. Int J Immunopharm. 1999;21:1–14. - PubMed
    1. Dockrell DH, Kinghorn GR. Imiquimod and Resiquimod as novel immunomodulators. J Antimicrob Chemother. 2001;48:751–5. - PubMed